{
    "nctId": "NCT00038103",
    "briefTitle": "Open-Label Study Of Exemestane With Or Without Celecoxib In Postmenopausal Women With ABC Having Progressed On Tamoxifen",
    "officialTitle": "Open-Label, Multicentre, Controlled Study Of Exemestane (Aromasin\u00ae) With Or Without Celecoxib (Celebrex\u00ae) In Postmenopausal Women With Advanced Breast Cancer (ABC) Having Progressed On Tamoxifen",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Neoplasms",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 111,
    "primaryOutcomeMeasure": "Number of Subjects With Clinical Benefit",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Postmenopausal female patient with histologically or cytologically confirmed breast cancer having progressed on Tamoxifen.\n* Advanced disease: patients with advanced breast carcinoma with disease progression who had progressed/relapsed following \\> 8 weeks of treatment with Tamoxifen for advanced disease; or progressed during adjuvant Tamoxifen for at least 6 or 12 months depending on receptor status; or progressed within 12 months from completion of adjuvant treatment with Tamoxifen.\n* at least one measurable lesion\n\nExclusion Criteria:\n\n* More than one previous chemotherapy and/or more than one hormonotherapy for advanced disease.\n* Previous hormonotherapy for advanced disease other than Tamoxifen.\n* Myocardial infarction within previous 6 mo",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}